TRML(Delisted)
Tourmaline BioยทNASDAQ
--
--(--)
TRML Profile
Tourmaline Bio, Inc.
A late-stage clinical biotechnology company
27 West 24th Street, Suite 702, New York, NY 10010
--
Tourmaline Bio, Inc., is incorporated in Delaware. The company is a late-stage clinical biotechnology company with a mission to develop transformative medicines that dramatically improve the lives of patients with life-changing immune diseases. Their lead project, TOUR006, is an anti-IL-6 antibody that exhibits different properties, including high binding affinity to IL-6 and a naturally long half-life. To date, TOUR006 has studied more than 400 autoimmune patients in six clinical trials. The company plans to develop TOUR006 for the treatment of thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its primary and secondary indications, respectively, with other indications under consideration.
